Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients

Phase 4

• Conditions: Hypertension

• Registration Number: JPRN-C000000267
• Lead Sponsor: EBM Collaborating Research Center in Kyoto University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-10-30
• Study Completion: 2005-12-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 4000

Inclusion Criteria

Not provided

Exclusion Criteria

1.SBP ≥200 mmHg or DBP ≥120 mmHg in a sitting position 2.Type I diabetes mellitus 3.History of myocardial infarction or cerebrovascular accidents within 6 months prior to the screening 4.PTCA or CABG done within 6 months of screening or scheduled 5.Current treatment for congestive cardiac failure (NYHA functional class II or severer) or ejection fraction <40% 6.Coronary artery disease requiring beta blocker or calcium channel blocker 7.Atrial fibrillation or atrial flutter 8.Renal dysfunction (serum creatinine ≥3 mg/dl) 9.Hepatic dysfunction (AST and/or ALT ≥100 IU/l) 10.A history of malignant tumor within 5 years of enrollment or suspected 11.Contraindication for candesartan cilexetil or amlodipine besilate 12.Pregnancy, possible pregnancy, or plan to conceive a child within 5 years of enrollment 13.Not suited to the clinical trail as judged by a collaborating physician 14.Inability to give informed consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified